Stryker is adding Quest Diagnostics Chairman, President and CEO James E. Davis to its board, effective Jan. 1, 2027. The board expanded from 11 seats to 12 to create the opening and selected Davis to fill it. Stryker announced the appointment on Nov. 9, following the board’s action on Nov. 3.
Davis brings leadership experience in diagnostics, medical technology and global operations. He will join the board as a nonemployee director and has not been assigned to a board committee.
Key details
- Davis has led Quest Diagnostics as president and CEO since November 2022 and became its chairman in April 2023.
- Before Quest, he was CEO of medical-device company InSightec. Earlier, he spent about 20 years in senior roles at General Electric’s healthcare and aviation businesses, including five years leading GE’s MRI business. He previously worked at McKinsey & Company.
- Stryker will compensate Davis on the same basis as its other nonemployee directors. It will also enter into its standard director indemnification agreement with him.
- Stryker Chair and CEO Kevin Lobo said Davis’s healthcare experience, operational leadership and knowledge of medical technology would support the company’s strategy.
What changes
Davis’s appointment gives Stryker’s board one additional seat, bringing its authorized size to 12 beginning Jan. 1. The announcement does not specify a committee role for him.